NovAccess Global Inc. XSNX
0.00 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.0002 Day range 0.0002
0.0001 52-week range 0.05
- YTD
- 0.00%
- 1 year
- -50.00%
- Market cap
- 6.17K
- EPS (ttm)
- -0.06
- YTD return
- 0.00%
- 1-year return
- -50.00%
- Volume
- 55.10K
- Avg volume
- 1.18K
- Open
- 0.0002
- Previous close
- 0.0001
- Day's range
- 0.0002 – 0.0002
- 52-week range
- 0.0001 – 0.05
- Earnings date
- Aug 11, 2023
3M 0.0000 (0.00%)
Next earnings
Aug 11, 2023
Expected Aug 11, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Jun 1, 2024 | 0.00 | -0.02 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.02 | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | 0.01 | — | — |
| Feb 9, 2024 | Sep 1, 2023 | 0.00 | -0.08 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
News
Financial Contrast: NovAccess Global (OTCMKTS:XSNX) vs. Lexicon Pharmaceuticals (NASDAQ:LXRX) 
NovAccess Global (OTCMKTS:XSNX) versus Roivant Sciences (NASDAQ:ROIV) Financial Review 
NovAccess Global Advisory on Annual Meeting of Shareholders 
NovAccess Global Announces New License to Advance its Immunotherapy Platform 
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders 
NovAccess Global Announces $10.7 Million Financing 
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit 
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board 
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform 
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
Your note
Sign in to keep a note on XSNX — it syncs with the Stock Master app.